EN
European Growth Stocks With Strong Insider Confidence
As European markets grapple with inflationary pressures and geopolitical tensions, investors are increasingly seeking stability and potential growth opportunities within the region. In this environment, companies with high insider ownership often signal a strong alignment between management and shareholder interests, suggesting confidence in their long-term prospects.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| Pharma Mar (BME:PHM) | 12.1% | 39.9% |
| Kuros Biosciences (SWX:KURN) | 23.7% | 65.6% |
| KebNi (OM:KEBNI B) | 13.1% | 110.7% |
| Gold Road International (OB:GOLDR) | 36.7% | 89.8% |
| Egetis Therapeutics (OM:EGTX) | 18.4% | 49.5% |
| CTT Systems (OM:CTT) | 17.4% | 55.3% |
| Clavister Holding AB (publ.) (OM:CLAV) | 19.4% | 41.1% |
| Bonesupport Holding (OM:BONEX) | 10.6% | 32.1% |
| Bergen Carbon Solutions (OB:BCS) | 11.9% | 52% |
| 2G Energy (XTRA:2GB) | 13.4% | 35.6% |
Let's take a closer look at a couple of our picks from the screened companies.
DNO (OB:DNO)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: DNO ASA is involved in the exploration, development, and production of oil and gas assets across the Middle East, the North Sea, and West Africa, with a market capitalization of NOK22.80 billion.
Operations: The company's revenue from oil and gas activities amounts to $2.42 billion.
Insider Ownership: 13.3%
DNO ASA, a European company with significant insider ownership, shows promising earnings growth potential, projected at 30.81% annually over the next three years. Recent operating results highlight increased net production in Kurdistan and the North Sea, contributing to improved financial performance with sales reaching US$760.5 million in Q2 2026. Despite anticipated revenue declines of 2.1% annually, insider buying activity suggests confidence in future profitability and operational resilience amidst market challenges.
- Navigate through the intricacies of DNO with our comprehensive analyst estimates report here.
- Our comprehensive valuation report raises the possibility that DNO is priced higher than what may be justified by its financials.
Mowi (OB:MOWI)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Mowi ASA is a seafood company that produces and sells Atlantic salmon products globally, with a market capitalization of approximately NOK113.89 billion.
Operations: Mowi ASA's revenue is primarily generated from its Farming segment (€3.81 billion), Sales & Marketing - Markets (€4.36 billion), Sales and Marketing - Consumer Products (€3.94 billion), and Feed operations (€992 million).
Insider Ownership: 15.9%
Mowi, with substantial insider ownership, is forecast to achieve significant earnings growth of 22.35% annually over the next three years, outpacing the Norwegian market. Despite a high debt level and recent net losses—EUR 164 million in Q2 2026—the company reported increased harvest volumes and revenue growth of EUR 1.6 billion for the quarter. Trading at a significant discount to its estimated fair value suggests potential undervaluation amidst these mixed financial results.
- Click here and access our complete growth analysis report to understand the dynamics of Mowi.
- The valuation report we've compiled suggests that Mowi's current price could be quite moderate.
Medicover (OM:MCOV B)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Medicover AB (publ) offers healthcare and diagnostic services in Poland, Sweden, and internationally, with a market cap of SEK41.94 billion.
Operations: The company generates revenue from two main segments: Diagnostic Services, contributing €789.10 million, and Healthcare Services, providing €1.71 billion.
Insider Ownership: 11.4%
Medicover, with significant insider ownership, is expected to see earnings grow significantly at 20.8% annually over the next three years, surpassing Swedish market averages. Despite recent substantial insider selling and low forecasted return on equity of 14.6%, Medicover trades at a notable discount to its estimated fair value. The company plans to divest its Medicover Hospitals India unit to KKR-managed funds, potentially impacting future growth dynamics positively or negatively depending on execution outcomes.
- Get an in-depth perspective on Medicover's performance by reading our analyst estimates report here.
- Our valuation report unveils the possibility Medicover's shares may be trading at a discount.
Make It Happen
- Investigate our full lineup of 200 Fast Growing European Companies With High Insider Ownership right here.
- Contemplating Other Strategies? AI is about to change healthcare. These 124 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com